Bausch Health Companies (NYSE:BHC) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share guidance of – for the period. The company issued revenue guidance of $8.60 billion-$8.80 billion, compared to the consensus revenue estimate of $8.66 billion.
Shares of BHC stock traded down $3.48 during trading hours on Tuesday, hitting $27.94. 10,284,975 shares of the company were exchanged, compared to its average volume of 4,614,434. The business has a 50 day moving average of $31.21 and a two-hundred day moving average of $25.54. The company has a market capitalization of $9.94 billion, a PE ratio of -5.13, a PEG ratio of 0.54 and a beta of 1.47. The company has a current ratio of 1.20, a quick ratio of 0.94 and a debt-to-equity ratio of 37.16. Bausch Health Companies has a 52 week low of $14.86 and a 52 week high of $34.80.
Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Tuesday, February 23rd. The company reported $1.33 EPS for the quarter, topping the Zacks’ consensus estimate of $1.12 by $0.21. Bausch Health Companies had a negative net margin of 23.92% and a positive return on equity of 173.20%. The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.22 billion. On average, research analysts forecast that Bausch Health Companies will post 3.75 EPS for the current year.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Further Reading: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.